New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
11:51 EDTAAL, GILDStocks with call strike movement; AAL GILD
American Airlines (ALL) August 44 call option implied volatility increased 4% to 39, Gilead (GILD) August 80 call option implied volatility decreased 2% to 34 according to IVolatility.
News For AAL;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 24, 2015
10:32 EDTAALAmerican Airlines sees Q3 mainline CASM ex-items up 3%-5%
Subscribe for More Information
10:29 EDTAALAmerican Airlines sees 2015 total system capacity up 1%
Subscribe for More Information
09:36 EDTAALActive equity options trading on open
Subscribe for More Information
09:36 EDTAALAmerican Airlines sees MD-80 planes retired from fleet by 2017
Subscribe for More Information
09:15 EDTAALAmerican Airlines says combined company exceeding estimated for synergies
Management stated that the company doesn't know when PRASM will turn positive. Management further stated that they are bullish on the company and bullish on the stock and as long as the market allows for it, share repurchases will continue.
09:14 EDTAALOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Amazon (AMZN), up 20.7%... Pandora (P), up 10.3%... Juniper (JNPR), up 9.1%... Visa (V), up 6.7%... Starbucks (SBUX), up 5%... Skyworks (SWKS), up 2.6%... American Airlines (AAL), up 2.1%. ALSO HIGHER: SolarCity (SCTY), up 2.5% after being upgraded to Outperform from Neutral at Baird. DOWN AFTER EARNINGS: Tripadvisor (TRIP), down 8.5%... Biogen (BIIB), down 14.1%.
09:00 EDTAALAmerican Airlines sees 1%-2% capacity growth in FY15
Subscribe for More Information
08:58 EDTAALAmerican Airlines sees Q3 pre-tax margin ex-items 16%-18%
Subscribe for More Information
08:56 EDTAALAmerican Airlines authorizes additional $2B share repurchase program
Subscribe for More Information
07:05 EDTAALAmerican Airlines reports Q2 consolidated PRASM down 6.9% to 13.57c
Subscribe for More Information
07:04 EDTAALAmerican Airlines reports Q2 EPS excluding items $2.62, consensus $2.60
Subscribe for More Information
06:27 EDTGILDGilead price target raised to $131 from $120 at Piper Jaffray
Subscribe for More Information
July 23, 2015
15:20 EDTAALAmerican Airlines July weekly 41.5 straddle priced for 3.8% movement into Q2
15:05 EDTAALNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include AbbVie (ABBV), consensus $1.06... Biogen (BIIB), consensus $4.10... Simon Property Group (SPG), consensus $2.36... State Street (STT), consensus $1.37... V.F. Corp. (VFC), consensus 36c... Johnson Controls (JCI), consensus 91c... American Airlines (AAL), consensus $2.60... Rockwell Collins (COL), consensus $1.30... Cabot Oil & Gas (COG), consensus 4c... Lear (LEA), consensus $2.48... Encana (ECA), consensus (15c).
15:00 EDTAALProposed bill would cut airline bag fees, Bloomberg reports
Subscribe for More Information
14:15 EDTAALAmerican Airlines technical notes before results
Subscribe for More Information
12:45 EDTGILDGilead July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
06:45 EDTAALAmerican Airlines July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
July 21, 2015
14:12 EDTGILDGilead reports study of E/C/F/TAF met primary endpoint
Gilead Sciences announced detailed 48-week data from an open-label Phase 3 study evaluating its investigational once-daily single tablet regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg, or E/C/F/TAF, among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada. Among the 1,436 patients who were randomized in the study, virologic success rates at Week 48 were higher in patients taking E/C/F/TAF, 97% versus 93% for all TDF-based regimens; difference in percentages: 4.1%, 95% CI: 1.6% to 6.7%. The rates of virologic failure were similar between the two arms, with E/C/F/TAF, 1.0% and TDF-based regimen, 1.3%. General safety was similar between the two arms through 48 weeks of treatment, with similar percentages of patients in each group having any adverse events. Adverse events leading to treatment discontinuation were more common among patients treated with a TDF-based regimen.
July 20, 2015
07:33 EDTGILDInternational AIDS Society to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use